Abstract
De novo drug design methods such as receptor or protein based pharmacophore modeling present a unique opportunity to generate novel ligands by employing the potential binding sites even when no explicit ligand information is known for a particular target. Recent developments in molecular modeling programs have enhanced the ability of early programs such as LUDI or Pocket that not only identify the key interactions or hot spots at the suspected binding site, but also and convert these hot spots into three-dimensional search queries and virtual screening of the property filtered synthetic libraries. Together with molecular docking studies and consensus scoring schemes they would enrich the lead identification processes. In this review, we discuss the ligand and receptor based de novo drug design approaches with selected examples.
Keywords: 3D-QSAR, analog based drug design, consensus scoring, de novo drug design, fragment based drug design, pharmacophore, receptor based pharmacophore.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Revisiting De Novo Drug Design: Receptor Based Pharmacophore Screening
Volume: 14 Issue: 16
Author(s): Harikishore Amaravadhi, Kwanghee Baek and Ho Sup Yoon
Affiliation:
Keywords: 3D-QSAR, analog based drug design, consensus scoring, de novo drug design, fragment based drug design, pharmacophore, receptor based pharmacophore.
Abstract: De novo drug design methods such as receptor or protein based pharmacophore modeling present a unique opportunity to generate novel ligands by employing the potential binding sites even when no explicit ligand information is known for a particular target. Recent developments in molecular modeling programs have enhanced the ability of early programs such as LUDI or Pocket that not only identify the key interactions or hot spots at the suspected binding site, but also and convert these hot spots into three-dimensional search queries and virtual screening of the property filtered synthetic libraries. Together with molecular docking studies and consensus scoring schemes they would enrich the lead identification processes. In this review, we discuss the ligand and receptor based de novo drug design approaches with selected examples.
Export Options
About this article
Cite this article as:
Amaravadhi Harikishore, Baek Kwanghee and Yoon Sup Ho, Revisiting De Novo Drug Design: Receptor Based Pharmacophore Screening, Current Topics in Medicinal Chemistry 2014; 14 (16) . https://dx.doi.org/10.2174/1568026614666140929115506
DOI https://dx.doi.org/10.2174/1568026614666140929115506 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances of Kinesin Motor Inhibitors and their Clinical Progress
Reviews on Recent Clinical Trials Anticancer Drugs Designed by Mother Nature: Ancient Drugs but Modern Targets
Current Pharmaceutical Design ABC Transporter Inhibitors in Reversing Multidrug Resistance to Chemotherapy
Current Drug Targets Physico-chemical and Biological Evaluation of Flavonols: Fisetin, Quercetin and Kaempferol Alone and Incorporated in beta Cyclodextrins
Anti-Cancer Agents in Medicinal Chemistry Primary Sjogren’s Syndrome and the Type I Interferon System
Current Pharmaceutical Biotechnology Excessive Indoor Tanning as a Behavioral Addiction: A Literature Review
Current Pharmaceutical Design New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Placental Drug Transporters
Current Drug Metabolism Update on Evidence that Support a Role of Solar Ultraviolet-B Irradiance in Reducing Cancer Risk
Anti-Cancer Agents in Medicinal Chemistry Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Induced Pluripotent Stem Cells (iPSCs) Derived from Different Cell Sources and their Potential for Regenerative and Personalized Medicine
Current Molecular Medicine Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets Microfluidic approaches to synchrotron radiation-based Fourier transform infrared (SR-FTIR) spectral microscopy of living biosystems
Protein & Peptide Letters Therapeutic Gene Products Delivery by Neuron Stem Cells
Current Pharmaceutical Biotechnology The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry An Update on NLRP3 Inflammasome Activation by Engineered Nanomaterials
Current Bionanotechnology (Discontinued) HLA Class I Expression, Tumor Escape and Cancer Progression
Current Cancer Therapy Reviews Characterization of MHC Ligands for Peptide Based Tumor Vaccination
Current Pharmaceutical Design